ClinicalTrials.gov
ClinicalTrials.gov Menu

Clinical Evaluation of Nelarabine (506U78)in Japanese Patients With Leukemia or Lymphoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00406757
Recruitment Status : Completed
First Posted : December 4, 2006
Last Update Posted : November 13, 2017
Sponsor:
Information provided by (Responsible Party):
GlaxoSmithKline

Brief Summary:
In Japan, patients with relapsed or refractory T-ALL/T-LBL represent an extremely small patient population. While the small number of patients presents a practical limitation to the size of a clinical trial, patients whose disease has not responded to or has relapsed after treatment with multiple prior chemotherapy regimens have no accepted standard therapies available. Japanese leukemia experts have expressed interest in evaluating 506U78 in Japanese patients with relapsed or refractory T-ALL/T-LBL. In order to obtain safety, tolerability, and pharmacokinetic data of 506U78 in Japanese patients, this study is designed to maximize the contribution of each available patient.

Condition or disease Intervention/treatment Phase
Leukaemia, Lymphoblastic, Acute and Lymphoma, Lymphoblastic Drug: Nelarabine injection 400mg/m2 Drug: Nelarabine injection 650mg/m2 Drug: Nelarabine injection 1000mg/m2 Drug: Nelarabine injection 1500mg/m2 Phase 1

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 13 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Clinical Evaluation of 506U78 in Japanese Patients With Relapsed or Refractory T-cell Acute Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma.
Actual Study Start Date : August 30, 2006
Actual Primary Completion Date : July 15, 2009
Actual Study Completion Date : July 15, 2009


Arm Intervention/treatment
Active Comparator: Pediatric Arm 1

Cycle 1: Nelarabine 400mg/m2 will be administered once daily from Day 1 to Day 5 followed by 16 days of off-dose.

Cycle 2 and subsequent Cycles: Nelarabine 650mg2 will be administered once daily from Day 1 to Day 5 followed by 16 days of off-dose.

Drug: Nelarabine injection 400mg/m2

Cycle 1: Nelarabine 400mg/m2 will be administered once a day from Day 1 to Day 5.

Cycle 2 and subsequent Cycles: Nelarabine 650mg/m2 will be administered once daily from Day 1 to DAy 5.

Active Comparator: Pediatric Arm 2
Cycle 1 and subsequent Cycles: Nelarabine 650mg/m2 will be administered once daily from Day 1 to Day 5 followed by 16 days of off-dose.
Drug: Nelarabine injection 650mg/m2
Nelarabine 650mg/m2 will be administered once a day from Day 1 to Day 5.
Active Comparator: Adult Arm 1

Cycle 1: Nelarabine 1000mg/m2 will be administered once daily on Days 1, 3 and 5 followed by 16 days of off-dose.

Cycle 2 and subsequent Cycles: Nelarabine 1500mg/m2 will be administered once daily on Days 1, 3 and 5 followed by 16 days of off-dose.

Drug: Nelarabine injection 1000mg/m2

Cycle 1: Nelarabine 1000mg/m2 will be administered once a day on Days 1, 3 and 5.

Cycle 2 and subsequent Cycles: Nelarabine 1500mg/m2 will be administered once a day on Days 1, 3 and 5.

Active Comparator: Adult Arm 2
Cycle 1 and subsequent Cycles: Nelarabine 1500mg/m2 will be administered once daily on Days 1, 3 and 5 followed by 16 days of off-dose.
Drug: Nelarabine injection 1500mg/m2
Nelarabine 1500mg/m2 will be administered once a day on Days 1, 3 and 5.
Active Comparator: Pediatric Arm 3
Nelarabine 650mg/m2 will be administered once a day from Day 1 to Day 5.
Drug: Nelarabine injection 650mg/m2
Nelarabine 650mg/m2 will be administered once a day from Day 1 to Day 5.



Primary Outcome Measures :
  1. Adverse events, changes from baseline in physical examination and clinical laboratory parameters12-lead ECGAssessment of pharmacokinetic endpoints of 506U78, ara-G and intracellular ara-GTP concentration. [ Time Frame: Day 21 ]

Secondary Outcome Measures :
  1. Evaluation of response (e.g., CR, CR*) in patients with bone marrow involvement. [ Time Frame: Day 21 ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   up to 64 Years   (Child, Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Histologic or cytogenetic documented diagnosis of T-ALL or T-LBL.
  • Disease that is refractory to at least one prior chemotherapy regimen, or has relapsed following complete remission to at least one prior chemotherapy regimen.
  • At least 4 weeks since the last dose of prior last chemotherapy, or radiotherapy before beginning treatment with 506U78 (2 weeks is permitted if growth of blast cells is significant).
  • Adequate function of other organ systems as measured as follows.Serum creatinine is less than 1.5 times of upper limit of normal and estimated creatinine clearance >=50 mL/min. Hepatic transaminases (SGPT and SGOT) <=3 x upper limit of normal, bilirubin is less than 1.5 times of upper limit of normal(<=5 x upper limit of normal if it is related by T-ALL or T-LBL).
  • Adequate performance status (ECOG-PS<=2).
  • Capable of giving informed consent which includes compliance with the requirements and restrictions listed in the consent form.
  • Patient is willing to accept hospitalization during the blood sampling for pharmacokinetic measurement (i.e., Cohort 1: for pharmacokinetic sample collection during both cycle 1 and 2; and Cohort 2: for pharmacokinetic sample collection during cycle 1).
  • Female subjects who are of child-bearing potential must have a negative pregnancy test at the Screening Visit and agree to utilize contraceptive methods during participation in the study and for at least six months following the last dose of 506U78 Injection. Female subjects may be defined as of non-child-bearing potential if they are physiologically incapable of becoming pregnant, including any female who is post-menopausal. For purposes of this study, postmenopausal is defined as one year without menses.

Exclusion Criteria:

  • Active infection at time of treatment.
  • Concurrent disease or condition that would make the subject inappropriate for study participation.
  • Receiving any other anticancer agents or enrolled on any investigational study during the course of the study.
  • Patients must have recovered to Grade I or less toxicity of all previous chemotherapy prior to treatment.
  • History of seizure disorder within one year prior to the date of informed consent.
  • Pregnancy (as demonstrated by a positive pregnancy test at pre-study/screening) or breastfeeding. Fertile women and men must practice adequate contraception throughout the study and at least 6 month after the last dose of study drug.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00406757


Locations
Japan
GSK Investigational Site
Aichi, Japan, 460-0001
GSK Investigational Site
Tokyo, Japan, 104-0045
GSK Investigational Site
Tokyo, Japan, 104-8560
Sponsors and Collaborators
GlaxoSmithKline
Investigators
Study Director: GSK Clinical Trials GlaxoSmithKline

Additional Information:
Publications:
Responsible Party: GlaxoSmithKline
ClinicalTrials.gov Identifier: NCT00406757     History of Changes
Other Study ID Numbers: PGA105446
First Posted: December 4, 2006    Key Record Dates
Last Update Posted: November 13, 2017
Last Verified: November 2017

Keywords provided by GlaxoSmithKline:
T-cell
T-ALL
T-LBL
506U78
ara-G
ara-GTP
Lymphoma
Leukemia

Additional relevant MeSH terms:
Lymphoma
Leukemia
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Neoplasms by Histologic Type
Neoplasms
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Leukemia, Lymphoid